Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 79


Population Pharmacokinetic Analysis of Fluticasone Furoate/Umeclidinium Bromide/Vilanterol in Patients with Chronic Obstructive Pulmonary Disease.

Mehta R, Farrell C, Hayes S, Birk R, Okour M, Lipson DA.

Clin Pharmacokinet. 2019 Jul 19. doi: 10.1007/s40262-019-00794-w. [Epub ahead of print]


Blood eosinophils and treatment response with triple and dual combination therapy in chronic obstructive pulmonary disease: analysis of the IMPACT trial.

Pascoe S, Barnes N, Brusselle G, Compton C, Criner GJ, Dransfield MT, Halpin DMG, Han MK, Hartley B, Lange P, Lettis S, Lipson DA, Lomas DA, Martinez FJ, Papi A, Roche N, van der Valk RJP, Wise R, Singh D.

Lancet Respir Med. 2019 Jul 4. pii: S2213-2600(19)30190-0. doi: 10.1016/S2213-2600(19)30190-0. [Epub ahead of print]


Efficacy and safety of the dual bronchodilator combination umeclidinium/vilanterol in COPD by age and airflow limitation severity: A pooled post hoc analysis of seven clinical trials.

Ray R, Tombs L, Naya I, Compton C, Lipson DA, Boucot I.

Pulm Pharmacol Ther. 2019 Aug;57:101802. doi: 10.1016/j.pupt.2019.101802. Epub 2019 May 13.


Impact of prior and concurrent medication on exacerbation risk with long-acting bronchodilators in chronic obstructive pulmonary disease: a post hoc analysis.

Naya I, Tombs L, Lipson DA, Boucot I, Compton C.

Respir Res. 2019 Mar 26;20(1):60. doi: 10.1186/s12931-019-1027-9.


Soil microbial responses to drought and exotic plants shift carbon metabolism.

Pérez Castro S, Cleland EE, Wagner R, Sawad RA, Lipson DA.

ISME J. 2019 Jul;13(7):1776-1787. doi: 10.1038/s41396-019-0389-9. Epub 2019 Mar 14.


Preventing clinically important deterioration with single-inhaler triple therapy in COPD.

Naya I, Compton C, Ismaila AS, Birk R, Brealey N, Tabberer M, Zhu CQ, Lipson DA, Criner G.

ERJ Open Res. 2018 Oct 3;4(4). pii: 00047-2018. doi: 10.1183/23120541.00047-2018. eCollection 2018 Oct.


The Efficacy and Safety of Once-daily Fluticasone Furoate/Umeclidinium/Vilanterol Versus Twice-daily Budesonide/Formoterol in a Subgroup of Patients from China with Symptomatic COPD at Risk of Exacerbations (FULFIL Trial).

Zheng J, Zhong N, Wang C, Huang Y, Chen P, Wang L, Hui F, Zhao L, Wang H, Luo L, Du X, Han Goh A, Lipson DA.

COPD. 2018 Jun-Aug;15(4):334-340. doi: 10.1080/15412555.2018.1481022. Epub 2018 Sep 28.


Preventing Clinically Important Deterioration of COPD with Addition of Umeclidinium to Inhaled Corticosteroid/Long-Acting β2-Agonist Therapy: An Integrated Post Hoc Analysis.

Naya IP, Tombs L, Lipson DA, Compton C.

Adv Ther. 2018 Oct;35(10):1626-1638. doi: 10.1007/s12325-018-0771-4. Epub 2018 Sep 6.


Single-Inhaler Triple versus Dual Therapy in Patients with COPD.

Lipson DA, Criner GJ, Lomas DA.

N Engl J Med. 2018 Aug 9;379(6):592-593. doi: 10.1056/NEJMc1807380. No abstract available.


Efficacy of Umeclidinium/Vilanterol in Elderly Patients with COPD: A Pooled Analysis of Randomized Controlled Trials.

Ray R, Tombs L, Asmus MJ, Boucot I, Lipson DA, Compton C, Naya I.

Drugs Aging. 2018 Jul;35(7):637-647. doi: 10.1007/s40266-018-0558-y.


Population Pharmacokinetic Analysis of Fluticasone Furoate/Umeclidinium/Vilanterol via a Single Inhaler in Patients with COPD.

Mehta R, Pefani E, Beerahee M, Brealey N, Barnacle H, Birk R, Zhu CQ, Lipson DA.

J Clin Pharmacol. 2018 Nov;58(11):1461-1467. doi: 10.1002/jcph.1253. Epub 2018 May 15.


Single-inhaler triple therapy in symptomatic COPD patients: FULFIL subgroup analyses.

Halpin DMG, Birk R, Brealey N, Criner GJ, Dransfield MT, Hilton E, Lomas DA, Zhu CQ, Lipson DA.

ERJ Open Res. 2018 May 4;4(2). pii: 00119-2017. doi: 10.1183/23120541.00119-2017. eCollection 2018 Apr.


Once-Daily Single-Inhaler Triple versus Dual Therapy in Patients with COPD.

Lipson DA, Barnhart F, Brealey N, Brooks J, Criner GJ, Day NC, Dransfield MT, Halpin DMG, Han MK, Jones CE, Kilbride S, Lange P, Lomas DA, Martinez FJ, Singh D, Tabberer M, Wise RA, Pascoe SJ; IMPACT Investigators.

N Engl J Med. 2018 May 3;378(18):1671-1680. doi: 10.1056/NEJMoa1713901. Epub 2018 Apr 18.


Effects of umeclidinium/vilanterol on exercise endurance in COPD: a randomised study.

Riley JH, Kalberg CJ, Donald A, Lipson DA, Shoaib M, Tombs L.

ERJ Open Res. 2018 Jan 5;4(1). pii: 00073-2017. doi: 10.1183/23120541.00073-2017. eCollection 2018 Jan.


Once-Daily Triple Therapy in Patients with COPD: Patient-Reported Symptoms and Quality of Life.

Tabberer M, Lomas DA, Birk R, Brealey N, Zhu CQ, Pascoe S, Locantore N, Lipson DA.

Adv Ther. 2018 Jan;35(1):56-71. doi: 10.1007/s12325-017-0650-4. Epub 2018 Jan 8.


Reply to Morice and Hart: Increased Propensity for Pneumonia with Fluticasone in Chronic Obstructive Pulmonary Disease.

Lipson DA, Barnacle H, Birk R, Brealey N, Locantore N, Lomas DA, Ludwig-Sengpiel A, Mohindra R, Tabberer M, Zhu CQ, Pascoe SJ.

Am J Respir Crit Care Med. 2018 May 1;197(9):1230-1231. doi: 10.1164/rccm.201711-2313LE. No abstract available.


Comparative Efficacy of Once-Daily Umeclidinium/Vilanterol and Tiotropium/Olodaterol Therapy in Symptomatic Chronic Obstructive Pulmonary Disease: A Randomized Study.

Feldman GJ, Sousa AR, Lipson DA, Tombs L, Barnes N, Riley JH, Patel S, Naya I, Compton C, Alcázar Navarrete B.

Adv Ther. 2017 Nov;34(11):2518-2533. doi: 10.1007/s12325-017-0626-4. Epub 2017 Nov 1.


Reply to Suissa and Ariel: The FULFIL Trial.

Lipson DA, Barnacle H, Birk R, Brealey N, Locantore N, Lomas DA, Ludwig-Sengpiel A, Mohindra R, Tabberer M, Zhu CQ, Pascoe SJ.

Am J Respir Crit Care Med. 2018 Feb 15;197(4):542-543. doi: 10.1164/rccm.201709-1831LE. No abstract available.


A pilot clinical trial of recombinant human angiotensin-converting enzyme 2 in acute respiratory distress syndrome.

Khan A, Benthin C, Zeno B, Albertson TE, Boyd J, Christie JD, Hall R, Poirier G, Ronco JJ, Tidswell M, Hardes K, Powley WM, Wright TJ, Siederer SK, Fairman DA, Lipson DA, Bayliffe AI, Lazaar AL.

Crit Care. 2017 Sep 7;21(1):234. doi: 10.1186/s13054-017-1823-x.


Once-Daily Triple Therapy in Patients with Advanced COPD: Healthcare Resource Utilization Data and Associated Costs from the FULFIL Trial.

Ismaila AS, Birk R, Shah D, Zhang S, Brealey N, Risebrough NA, Tabberer M, Zhu CQ, Lipson DA.

Adv Ther. 2017 Sep;34(9):2163-2172. doi: 10.1007/s12325-017-0604-x. Epub 2017 Sep 5.


Reply: "FULFIL an Unmet Need in Chronic Obstructive Pulmonary Disease" and "Triple Therapy in Chronic Obstructive Pulmonary Disease".

Lipson DA, Barnacle H, Birk R, Brealey N, Locantore N, Lomas DA, Ludwig-Sengpiel A, Mohindra R, Tabberer M, Zhu CQ, Pascoe SJ.

Am J Respir Crit Care Med. 2017 Oct 15;196(8):1083-1084. doi: 10.1164/rccm.201704-0818LE. No abstract available.


FULFIL Trial: Once-Daily Triple Therapy for Patients with Chronic Obstructive Pulmonary Disease.

Lipson DA, Barnacle H, Birk R, Brealey N, Locantore N, Lomas DA, Ludwig-Sengpiel A, Mohindra R, Tabberer M, Zhu CQ, Pascoe SJ.

Am J Respir Crit Care Med. 2017 Aug 15;196(4):438-446. doi: 10.1164/rccm.201703-0449OC.


A phase III randomised controlled trial of single-dose triple therapy in COPD: the IMPACT protocol.

Pascoe SJ, Lipson DA, Locantore N, Barnacle H, Brealey N, Mohindra R, Dransfield MT, Pavord I, Barnes N.

Eur Respir J. 2016 Aug;48(2):320-30. doi: 10.1183/13993003.02165-2015. Epub 2016 Jul 13.


Cold season emissions dominate the Arctic tundra methane budget.

Zona D, Gioli B, Commane R, Lindaas J, Wofsy SC, Miller CE, Dinardo SJ, Dengel S, Sweeney C, Karion A, Chang RY, Henderson JM, Murphy PC, Goodrich JP, Moreaux V, Liljedahl A, Watts JD, Kimball JS, Lipson DA, Oechel WC.

Proc Natl Acad Sci U S A. 2016 Jan 5;113(1):40-5. doi: 10.1073/pnas.1516017113. Epub 2015 Dec 22.


The complex relationship between microbial growth rate and yield and its implications for ecosystem processes.

Lipson DA.

Front Microbiol. 2015 Jun 16;6:615. doi: 10.3389/fmicb.2015.00615. eCollection 2015. No abstract available.


A Randomized Dose-Escalation Study of the Safety and Anti-Inflammatory Activity of the p38 Mitogen-Activated Protein Kinase Inhibitor Dilmapimod in Severe Trauma Subjects at Risk for Acute Respiratory Distress Syndrome.

Christie JD, Vaslef S, Chang PK, May AK, Gunn SR, Yang S, Hardes K, Kahl L, Powley WM, Lipson DA, Bayliffe AI, Lazaar AL.

Crit Care Med. 2015 Sep;43(9):1859-69. doi: 10.1097/CCM.0000000000001132.


Changes in microbial communities along redox gradients in polygonized Arctic wet tundra soils.

Lipson DA, Raab TK, Parker M, Kelley ST, Brislawn CJ, Jansson J.

Environ Microbiol Rep. 2015 Aug;7(4):649-57. doi: 10.1111/1758-2229.12301.


Elevated atmospheric CO2 stimulates soil fungal diversity through increased fine root production in a semiarid shrubland ecosystem.

Lipson DA, Kuske CR, Gallegos-Graves LV, Oechel WC.

Glob Chang Biol. 2014 Aug;20(8):2555-65. doi: 10.1111/gcb.12609. Epub 2014 May 26.


Autoantibodies to variable heavy (VH) chain Ig sequences in humans impact the safety and clinical pharmacology of a VH domain antibody antagonist of TNF-α receptor 1.

Holland MC, Wurthner JU, Morley PJ, Birchler MA, Lambert J, Albayaty M, Serone AP, Wilson R, Chen Y, Forrest RM, Cordy JC, Lipson DA, Bayliffe AI.

J Clin Immunol. 2013 Oct;33(7):1192-203. doi: 10.1007/s10875-013-9915-0. Epub 2013 Jul 6.


Metagenomic insights into anaerobic metabolism along an Arctic peat soil profile.

Lipson DA, Haggerty JM, Srinivas A, Raab TK, Sathe S, Dinsdale EA.

PLoS One. 2013 May 31;8(5):e64659. doi: 10.1371/journal.pone.0064659. Print 2013.


(3)He pO2 mapping is limited by delayed-ventilation and diffusion in chronic obstructive pulmonary disease.

Marshall H, Parra-Robles J, Deppe MH, Lipson DA, Lawson R, Wild JM.

Magn Reson Med. 2014 Mar;71(3):1172-8. doi: 10.1002/mrm.24779.


The adenosine 2A receptor agonist GW328267C improves lung function after acute lung injury in rats.

Folkesson HG, Kuzenko SR, Lipson DA, Matthay MA, Simmons MA.

Am J Physiol Lung Cell Mol Physiol. 2012 Aug 1;303(3):L259-71. doi: 10.1152/ajplung.00395.2011. Epub 2012 Jun 1.


A combined pulmonary-radiology workshop for visual evaluation of COPD: study design, chest CT findings and concordance with quantitative evaluation.

COPDGene CT Workshop Group, Barr RG, Berkowitz EA, Bigazzi F, Bode F, Bon J, Bowler RP, Chiles C, Crapo JD, Criner GJ, Curtis JL, Dass C, Dirksen A, Dransfield MT, Edula G, Erikkson L, Friedlander A, Galperin-Aizenberg M, Gefter WB, Gierada DS, Grenier PA, Goldin J, Han MK, Hanania NA, Hansel NN, Jacobson FL, Kauczor HU, Kinnula VL, Lipson DA, Lynch DA, MacNee W, Make BJ, Mamary AJ, Mann H, Marchetti N, Mascalchi M, McLennan G, Murphy JR, Naidich D, Nath H, Newell JD Jr, Pistolesi M, Regan EA, Reilly JJ, Sandhaus R, Schroeder JD, Sciurba F, Shaker S, Sharafkhaneh A, Silverman EK, Steiner RM, Strange C, Sverzellati N, Tashjian JH, van Beek EJ, Washington L, Washko GR, Westney G, Wood SA, Woodruff PG.

COPD. 2012 Apr;9(2):151-9. doi: 10.3109/15412555.2012.654923. Epub 2012 Mar 19.


Direct visualisation of collateral ventilation in COPD with hyperpolarised gas MRI.

Marshall H, Deppe MH, Parra-Robles J, Hillis S, Billings CG, Rajaram S, Swift A, Miller SR, Watson JH, Wolber J, Lipson DA, Lawson R, Wild JM.

Thorax. 2012 Jul;67(7):613-7. doi: 10.1136/thoraxjnl-2011-200864. Epub 2012 Jan 27.


A cost-effective and field-ready potentiostat that poises subsurface electrodes to monitor bacterial respiration.

Friedman ES, Rosenbaum MA, Lee AW, Lipson DA, Land BR, Angenent LT.

Biosens Bioelectron. 2012 Feb 15;32(1):309-13. doi: 10.1016/j.bios.2011.12.013. Epub 2011 Dec 16.


An oral inhibitor of p38 MAP kinase reduces plasma fibrinogen in patients with chronic obstructive pulmonary disease.

Lomas DA, Lipson DA, Miller BE, Willits L, Keene O, Barnacle H, Barnes NC, Tal-Singer R; Losmapimod Study Investigators.

J Clin Pharmacol. 2012 Mar;52(3):416-24. doi: 10.1177/0091270010397050. Epub 2011 Nov 16.


Inappropriate antibiotic prescribing in managed care subjects with influenza.

Misurski DA, Lipson DA, Changolkar AK.

Am J Manag Care. 2011 Sep;17(9):601-8.


Metabolic trade-offs and the maintenance of the fittest and the flattest.

Beardmore RE, Gudelj I, Lipson DA, Hurst LD.

Nature. 2011 Apr 21;472(7343):342-6. doi: 10.1038/nature09905. Epub 2011 Mar 27.


Microbial diversity in nonsulfur, sulfur and iron geothermal steam vents.

Benson CA, Bizzoco RW, Lipson DA, Kelley ST.

FEMS Microbiol Ecol. 2011 Apr;76(1):74-88. doi: 10.1111/j.1574-6941.2011.01047.x. Epub 2011 Feb 1.


Perfusion scintigraphy and patient selection for lung volume reduction surgery.

Chandra D, Lipson DA, Hoffman EA, Hansen-Flaschen J, Sciurba FC, Decamp MM, Reilly JJ, Washko GR; National Emphysema Treatment Trial Research Group.

Am J Respir Crit Care Med. 2010 Oct 1;182(7):937-46. doi: 10.1164/rccm.201001-0043OC. Epub 2010 Jun 10.


Overview of the perioperative management of lung volume reduction surgery patients.

Sharafkhaneh A, Falk JA, Minai OA, Lipson DA.

Proc Am Thorac Soc. 2008 May 1;5(4):438-41. doi: 10.1513/pats.200708-130ET. Review.


Tiotropium bromide.

Lipson DA.

Int J Chron Obstruct Pulmon Dis. 2006;1(2):107-14. Review.


Multiple regression method for pulmonary apparent diffusion coefficient measurement by hyperpolarized 3He MRI.

Yu J, Ishii M, Kadlecek S, Lipson DA, Emami K, Clark TW, Rajaei S, Rizi RR.

J Magn Reson Imaging. 2007 May;25(5):982-91.


Hyperpolarized 13C MRI of the pulmonary vasculature and parenchyma.

Ishii M, Emami K, Kadlecek S, Petersson JS, Golman K, Vahdat V, Yu J, Cadman RV, MacDuffie-Woodburn J, Stephen M, Lipson DA, Rizi RR.

Magn Reson Med. 2007 Mar;57(3):459-63.


Effects of abiotic factors on the phylogenetic diversity of bacterial communities in acidic thermal springs.

Mathur J, Bizzoco RW, Ellis DG, Lipson DA, Poole AW, Levine R, Kelley ST.

Appl Environ Microbiol. 2007 Apr;73(8):2612-23. Epub 2007 Jan 12.


Relationships between microbial community structure and soil processes under elevated atmospheric carbon dioxide.

Lipson DA, Blair M, Barron-Gafford G, Grieve K, Murthy R.

Microb Ecol. 2006 Apr;51(3):302-14. Epub 2006 Apr 6.


Nitrogen and carbon storage in alpine plants.

Monson RK, Rosenstiel TN, Forbis TA, Lipson DA, Jaeger CH 3rd.

Integr Comp Biol. 2006 Feb;46(1):35-48. doi: 10.1093/icb/icj006. Epub 2006 Jan 6.


Risk factors for death of patients with cystic fibrosis awaiting lung transplantation.

Belkin RA, Henig NR, Singer LG, Chaparro C, Rubenstein RC, Xie SX, Yee JY, Kotloff RM, Lipson DA, Bunin GR.

Am J Respir Crit Care Med. 2006 Mar 15;173(6):659-66. Epub 2005 Dec 30.

Supplemental Content

Loading ...
Support Center